Citations

Clear

1727 citation(s) found for "Fu, Alan".

The Prevalence and Significance of Staphylococcus aureus in Patients with Non–Cystic Fibrosis Bronchiectasis
Metersky, Mark L. , Aksamit, Timothy R. , Choate, Radmila , Daley, Charles L. , Daniels, M. Leigh Anne , DiMango, Angela, Eden, Edward , Griffith, David E. , Johnson, Margaret M. , Knowles, Michael R. , O’Donnell, Anne E., Olivier, Kenneth N., Thomashow, Byron, Tino, Gregory , Turino, Gerard, Winthrop, Kevin , Mannino, David M. , Johnson, Margaret , BARKER, ALAN ROBERT , Salathe, Matthias A. , Turino, Gerard M., Choate, Radmila , O'Donnell, Anne E

Mayo Clinic

Annals of the American Thoracic Society | January 18, 2018 | Volume: 15 | Issue: 3 | Pages: 365-370

10.1513/annalsats.201706-426oc | PMID 29345970 Get It

Abstract Rationale Staphylococcus aureus is commonly cultured from the sputum of patients with bronchiectasis; however, little is known about the prevalence of the organism in these patients, the characteristics of patients who have grown the organism, or its implications. Objectives Determine the relationship between S. aureus and pulmonary function, frequency of exacerbations, and frequency of hospitalization in patients with bronchiectasis Methods The Bronchiectasis Research Registry is a database of adults with non–cystic fibrosis bronchiectasis identified from 13 sites within the United States. Baseline and follow-up demographic, spirometric, microbiologic, and therapeutic data were entered into a central web-based database. Patients were grouped into three cohorts based on their previous respiratory cultures at the time of entry into the Registry: 1) no prior S. aureus or glucose-nonfermenting gram-negative bacilli (NF-GNB) (Pseudomonas, Stenotrophomonas, or Burkholderia spp.); 2) prior S. aureus at least once; or 3) no prior S. aureus but prior NF-GNB at least once. The association between S. aureus isolation and pulmonary function and frequency of exacerbations and hospital admissions was assessed, both at baseline and after 1 year of follow-up. Results S. aureus was cultured from 94 of 830 patients (11.3%) included in the analysis. Patients who had grown S. aureus before entry into the Registry had a frequency of prior exacerbations and baseline pulmonary function that was between that of patients who had grown NF-GNB and those who had grown neither NF-GNB or S. aureus. Similarly, at the first follow-up visit after study entry, patients who had grown S. aureus had a frequency of exacerbations and hospitalizations that was between those of patients who had grown NF-GNB and those who had grown neither NF-GNB nor S. aureus. However, in multivariate analysis, S. aureus was not associated with pulmonary function, frequency of exacerbation, or hospital admissions. There were no significant differences in patient characteristics or outcomes between patients who had methicillin-sensitive and methicillin-resistant S. aureus. Conclusions Staphylococcus aureus does not appear to be an independent risk factor for severe disease in patients with bronchiectasis enrolled in the Bronchiectasis Research Registry.
Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers o
Wu, Alan H.B. , Christenson, Robert H. , Greene, Dina N. , Jaffe, Allan S. , Kavsak, Peter A. , Ordóñez‐Llanos, Jordi , Apple, Fred S. , Jaffe, Allan S. , Greene, Dina , Kavsak, Peter

Mayo Clinic

Clinical Chemistry | January 17, 2018 | Volume: 64 | Issue: 4 | Pages: 645-655

10.1373/clinchem.2017.277186 | PMID 29343532 Get It

Abstract This document is an essential companion to the third iteration of the National Academy of Clinical Biochemistry [NACB,8 now the American Association for Clinical Chemistry (AACC) Academy] Laboratory Medicine Practice Guidelines (LMPG) on cardiac markers. The expert consensus recommendations were drafted in collaboration with the International Federation of Clinical Chemistry and Laboratory Medicine Task Force on Clinical Applications of Bio-Markers (IFCC TF-CB). We determined that there is sufficient clinical guidance on the use of cardiac troponin (cTn) testing from clinical practice groups. Thus, in this expert consensus document, we focused on clinical laboratory practice recommendations for high-sensitivity (hs)-cTn assays. This document utilized the expert opinion class of evidence to focus on the following 10 topics: (a) quality control (QC) utilization, (b) validation of the lower reportable analytical limits, (c) units to be used in reporting measurable concentrations for patients and QC materials, (d) 99th percentile sex-specific upper reference limits to define the reference interval; (e) criteria required to define hs-cTn assays, (f) communication with clinicians and the laboratory's role in educating clinicians regarding the influence of preanalytic and analytic problems that can confound assay results, (g) studies on hs-cTn assays and how authors need to document preanalytical and analytical variables, (h) harmonizing and standardizing assay results and the role of commutable materials, (i) time to reporting of results from sample receipt and sample collection, and (j) changes in hs-cTn concentrations over time and the role of both analytical and biological variabilities in interpreting results of serial blood collections.
PANDA: pathway and annotation explorer for visualizing and interpreting gene-centric data
Moore, Raymond M. , Egan, Jan B. , Kocher, Jean-Pierre A., Hart, Steven N. , Zimmermann, Michael T. , Oliver, Gavin R. , Bryce, Alan H.

Mayo Clinic

No container title available | January 12, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7287/peerj.preprints.1021v1 Get It

Objective: Bringing together genomics, transcriptomics, proteomics, and other –omics technologies is an important step towards developing highly personalized medicine. However, instrumentation has advances far beyond expectations and now we are able to generate data faster than it can be interpreted. Materials and Methods: We have developed PANDA ( P athway AND A nnotation) Explorer, a visualization tool that integrates gene-level annotation in the context of biological pathways to help interpret complex data from disparate sources. PANDA is a web-based application that displays data in the context of well-studied pathways like KEGG, BioCarta, and PharmGKB. PANDA represents data/annotations as icons in the graph while maintaining the other data elements (i.e. other columns for the table of annotations). Custom pathways from underrepresented diseases can be imported when existing data sources are inadequate. PANDA also allows sharing annotations among collaborators. Results : In our first use case, we show how easy it is to view supplemental data from a manuscript in the context of a user’s own data. Another use-case is provided describing how PANDA was leveraged to design a treatment strategy from the somatic variants found in the tumor of a patient with metastatic sarcomatoid renal cell carcinoma. Conclusion : PANDA facilitates the interpretation of gene-centric annotations by visually integrating this information with context of biological pathways. The application can be downloaded or used directly from our website http://bioinformaticstools.mayo.edu/research/panda-viewer/.
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Samson, Adel , Scott, Karen J. , Taggart, David J. , Wilson, Erica , Nuovo, Gerard J. , Thomson, Simon , Mathew, Ryan , Fuller, Martin, Kottke, Timothy, Thompson, Jill , Ilett, Elizabeth J. , Cockle, Julia , Hille, Philip van, Sivakumar, Gnanamurthy, Polson, Euan S. , Turnbull, Samantha , Appleton, Elizabeth , Migneco, G , Rose, Ailsa , Coffey, Matthew, Beirne, Deborah , Collinson, Fiona , Ralph, Christy , Anthoney, Alan , Twelves, Christopher , Furness, Andrew J.S. , Quezada, Sergio A. , Wurdak, Heiko , Errington‐Mais, Fiona , Pandha, Hardev , Harrington, Kevin J. , Selby, Peter J. , Vile, Richard G. , Griffin, Stephen , Stead, Lucy F. , Short, Susan , Melcher, Alan , Taggart, David , Wilson, Erica , Nuovo, Gerard J , Thomson, Simon , Mathew, Ryan K , Kottke, Timothy J, Thompson, Jill M, Ilett, Elizabeth J , Cockle, Julia V , Turnbull, Samantha J , Rose, Ailsa S , Beirne, Deborah A , Ralph, Christy , Alan Anthoney, D , Quezada, Sergio A , Wurdak, Heiko , Errington-Mais, Fiona , Selby, Peter J , Griffin, Stephen , Stead, Lucy F , Short, Susan C , Melcher, Alan A , Harrington, Kevin , West, Emma J. , Corns, Robert A. , Appleton, Elizabeth

Mayo Clinic

Science Translational Medicine | January 3, 2018 | Volume: 10 | Issue: 422 | Pages: No page available

10.1126/scitranslmed.aam7577 | PMID 29298869 Get It

Intravenous infusion of oncolytic reovirus in patients leads to infection of brain tumors, infiltration by cytotoxic T cells, and up-regulation of PD-L1.
Cross‐linkable graphene oxide embedded nanocomposite hydrogel with enhanced mechanics and cytocompatibility for tissue engineering
Liu, Xifeng , Miller, A. Lee , Waletzki, Brian E., Lu, Lichun , Miller, Alan Lee

Mayo Clinic

Journal of Biomedical Materials Research Part A | December 27, 2017 | Volume: 106 | Issue: 5 | Pages: 1247-1257

10.1002/jbm.a.36322 | PMID 29280326 Get It

AbstractGraphene oxide (GO) is an attractive material that can be utilized to enhance the modulus and conductivities of substrates and hydrogels. To covalently cross‐link graphene oxide sheets into hydrogels, abundant cross‐linkable double bonds were introduced to synthesize the graphene‐oxide‐tris‐acrylate sheet (GO‐TrisA). Polyacrylamide (PAM) nanocomposite hydrogels were then fabricated with inherent covalently and permanently cross‐linked GO‐TrisA sheets. Results showed that the covalently cross‐linked GO‐TrisA/PAM nanocomposite hydrogel had enhanced mechanical strength, thermo stability compared with GO/PAM hydrogel maintained mainly by hydrogen bonding between PAM chains and GO sheets. In vitro cell study showed that the covalently cross‐linked rGO‐TrisA/PAM nanocomposite hydrogel had excellent cytocompatibility after in situ reduction. These results suggest that rGO‐TrisA/PAM nanocomposite hydrogel holds great potential for tissue engineering applications. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 1247–1257, 2018.
Validation of insorption by blood analysis with comparisons of systemic and portal venous disappearances of D2O, Na24, and K42
Code, Charles F., Moll, Johann C., Orvis, Alan L.

Mayo Clinic

Journal of Applied Physiology | December 24, 2017 | Volume: 18 | Issue: 4 | Pages: 829-832

10.1152/jappl.1963.18.4.829 | PMID 14021916 Get It

The rates of disappearance D2O, Na22/24 and K42 from the arterial blood were determined in 17 dogs following rapid injection of the isotopes into the femoral and portal veins. Differences between systemic and portal venous injections were significant during the early phases of the disappearance of the isotopes (P < 0.05). Systemic insorption was simulated by continuous intravenous injection of D2O, Na22, and K42 at known rates into the femoral vein. The appearance of the isotopes in the arterial blood was determined repeatedly during and after their injection. The rate of injection (simulated insorption) was calculated using the mean systemic arterial disappearance rate. The differences between the calculated and actual rates of injection were insignificant. When portal insorption was simulated by constant injection of the isotope into the portal vein, the calculated rate of injection was not significantly different from the actual rate if the mean portal arterial disappearance curve was used in the calculation. When the systemic arterial disappearance curve was utilized, the calculated rate of injection was slightly faster than the actual rate. Submitted on July 11, 1962
Barrier Offered by Gastric Mucosa of Healthy Persons to Absorption of Sodium
Reitemeier, Richard J., Code, Charles F., Orvis, Alan L.

Mayo Clinic

Journal of Applied Physiology | December 24, 2017 | Volume: 10 | Issue: 2 | Pages: 261-266

10.1152/jappl.1957.10.2.261 | PMID 13428656 Get It

Comparison of Rate of Absorption of Labeled Sodium and Water From Upper Small Intestine of Healthy Human Beings
Reitemeier, Richard J., Code, Charles F., Orvis, Alan L.

Mayo Clinic

Journal of Applied Physiology | December 24, 2017 | Volume: 10 | Issue: 2 | Pages: 256-260

10.1152/jappl.1957.10.2.256 | PMID 13428655 Get It

Cholinergic stimulation enhances colonic motor activity, transit, and sensation in humans
Law, Ngai‐Moh, Bharucha, Adil E. , Undale, Anita S., Zinsmeister, Alan R.

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | December 24, 2017 | Volume: 281 | Issue: 5 | Pages: G1228-G1237

10.1152/ajpgi.2001.281.5.g1228 | PMID 11668032 Get It

The cholinesterase inhibitor neostigmine indirectly stimulates muscarinic M1/M2/M3 receptors, thereby reducing colonic distension in acute colonic pseudo-obstruction. We investigated the dose-response profile for the colonic sensorimotor effects of neostigmine and bethanechol, a direct muscarinic M2/M3 agonist in humans. A barostat-manometric assembly recorded phasic pressures, tone, and pressure-volume relationships (compliance) in the descending colon and rectum of 30 healthy subjects who received intravenous neostigmine (0.25, 0.75, or 1.5 mg; n = 15) or subcutaneous bethanechol (2.5, 5, or 10 mg; n = 15). Sensation to luminal distension was also assessed. Thereafter, the effects of neostigmine and bethanechol on colonic transit (geometric center) were compared with those of saline by scintigraphy in 21 subjects. Both drugs increased colonic phasic pressure activity, reduced rectal compliance, and enhanced urgency during rectal distension. Neostigmine also reduced colonic and rectal balloon volumes, reflecting increased tone by an average of 12% and 25% for the highest dose, respectively. Only neostigmine reduced colonic compliance, accelerated colonic transit [mean geometric center at 90 min 2.5 vs. 1.0 (placebo)], and increased pain perception during colonic distension. We conclude that neostigmine has more prominent colonic motor and sensory effects than bethanechol. Moreover, neostigmine induces coordinated colonic propulsion, perhaps by stimulating muscarinic M1 receptors in the myenteric plexus.
Viscoelastic properties of the human colon
Bharucha, Adil E. , Hubmayr, Rolf D., Ferber, Irene, Zinsmeister, Alan R.

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | December 24, 2017 | Volume: 281 | Issue: 2 | Pages: G459-G466

10.1152/ajpgi.2001.281.2.g459 | PMID 11447026 Get It

Our objectives were to characterize colonic viscoelastic properties of the human descending colon by assessing pressure-volume (P-V) relationships during barostatic balloon distension. In 16 healthy subjects, a balloon was inflated to 44 mmHg and then deflated to 0 mmHg in 4-mmHg steps at 10, 30, and 60 ml/min, allowing volume fluctuations to stabilize at each pressure increment. Thereafter, these “quasi-static” P-V curves were compared with “dynamic” distensions to 300 ml, at 1 and 10 ml/s, before and after intravenous atropine in another five subjects. During quasi-static curves, balloon volume stabilized at each pressure increment. Quasi-static P-V curves were reproducible within individuals and approximated to a power exponential function and revealed hysteresis, indicative of viscoelasticity. Body mass index influenced quasi-static P-V curves during inflation but not during deflation. The colon was less compliant during dynamic distensions at 10 ml/s than during quasi-static distensions. Atropine increased quasi-static compliance and attenuated differences between quasi-static and rapid distensions. We conclude that colonic viscoelastic properties can be assessed by quasi-static P-V curves. Rapid colonic distension activated neural reflexes, thereby reducing colonic compliance compared with quasi-static distensions.